Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast -2030

Table of Contents

1 Key Insights

2 Executive Summary

3 Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance
3.1 Total Market Share (%) Distribution of ARDS in 2017
3.2 Total Market Share (%) Distribution of ARDS in 2030

4 Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview
4.1 Introduction
4.1.1 Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
4.1.2 Development of Berlin Definition of ARDS
4.1.3 Problems with the AECC definition and subsequent Berlin definition of acute respiratory distress syndrome (ARDS)
4.2 Causes and Risk Factors
4.2.1 Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
4.3 Pathophysiology of Acute Respiratory Distress Syndrome (ARDS)
4.3.1 Inflammatory Processes in ARDS
4.3.2 The initial event of injury
4.3.3 Endothelial Damage
4.3.4 Specific Mediators of Inflammation and Lung Damage in ARDS
4.3.5 Altered Pulmonary Physiology in ARDS
4.3.6 Genetics
4.4 Stages of Acute Respiratory Distress Syndrome (ARDS)
4.5 Ventilator-Induced Lung Injury (VILI)
4.6 Major Determinants of VILI
4.6.1 Ventilator determinants of VILI
4.6.2 Patient determinants of VILI
4.7 Diagnosis of Acute Respiratory Distress Syndrome (ARDS)
4.7.1 Imaging techniques in ARDS
4.7.2 Imaging findings in ARDS
4.7.3 Differential Diagnosis

5 Case Reports
5.1 Coronavirus Disease 2019 (COVID-19) Complicated by Acute Respiratory Distress Syndrome: An Internist’s Perspective
5.2 A fulminant case of Acute Respiratory Distress Syndrome associated with mycoplasma pneumonia treated with nasal high-flow oxygen therapy
5.3 A case report of severe hypothermia complicated by acute respiratory distress syndrome

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Methodology

7 7MM Epidemiology Analysis
7.1 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
7.2 Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM

8 United States Epidemiology
8.1 Assumptions and Rationale
8.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United States
8.3 Severity-specific Incident Population of ARDS in the United States
8.4 Incident Population of ARDS by Risk Factors in the United States

9 EU5 Epidemiology
9.1 Germany Epidemiology
9.1.1 Assumptions and Rationale
9.1.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Germany
9.1.3 Severity-specific Incidence of ARDS in Germany
9.1.4 Incident Population of ARDS by Risk Factors in Germany
9.2 France Epidemiology
9.2.1 Assumptions and Rationale
9.2.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), in France
9.2.3 Severity-specific Incidence of ARDS in France
9.2.4 Incident Population of ARDS by Risk Factors in France
9.3 Italy Epidemiology
9.3.1 Assumptions and Rationale
9.3.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Italy
9.3.3 Severity-specific Incidence of ARDS in Italy
9.3.4 Incident Population of ARDS by Risk Factors in Italy
9.4 Spain Epidemiology
9.4.1 Assumptions and Rationale
9.4.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Spain
9.4.3 Severity-specific Incidence of ARDS in Spain
9.4.4 Incident Population of ARDS by Risk Factors in Spain
9.5 United Kingdom Epidemiology
9.5.1 Assumptions and Rationale
9.5.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United Kingdom
9.5.3 Severity-specific Incidence of ARDS in the United Kingdom
9.5.4 Incident Population of ARDS by Risk Factors in the United Kingdom

10 Japan Epidemiology
10.1 Assumptions and Rationale
10.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), ARDS in Japan
10.3 Severity-specific Incidence of ARDS in Japan
10.4 Incident Population of ARDS by Risk Factors in Japan

11 Treatment Algorithm, Current Treatment, and Medical Practices
11.1 Treatment and Support for Acute Respiratory Distress Syndrome (ARDS)
11.2 Treatment of ALI/ARDS associated with COVID-19

12 Proposed Guidelines for ARDS
12.1 An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome
12.2 The Clinical Practice Guideline by the Japanese Society of Respiratory Care Medicine and the Japanese Society of Intensive Care Medicine for the management of ARDS in Japan
12.3 Infectious Diseases Society of America (IDSA) Guidelines on the Treatment and Management of Patients with COVID-19
12.4 WHO guidance for the treatment ARDS associated with COVID-19

13 Unmet Needs

14 Off-Label Therapies for ARDS
14.1 Neuromuscular Blocking Agents (NMBAs)
14.1.1 Description
14.1.2 Mechanism of Action
14.1.3 Advantages and Disadvantages
14.1.4 Clinical Development
14.2 Inhaled Vasodilators
14.2.1 Description
14.2.2 Inhaled Pulmonary Vasodilators
14.2.3 Advantages and Disadvantages
14.2.4 Clinical Development
14.3 Corticosteroids
14.3.1 Description
14.3.2 Mechanism of Action
14.3.3 Advantages and Disadvantages
14.3.4 Clinical Development

15 Emerging Therapies
15.1 Key Cross Competition
15.1.1 List of Products in development for ARDS/ALI
15.2 Traumakine: Faron Pharmaceuticals
15.2.1 Product Description
15.2.2 Other Developmental Activities
15.2.3 Clinical Development
15.2.4 Clinical Trials Information
15.2.5 Safety and Efficacy
15.2.6 Product Profile
15.3 Bio-11006: BioMarck Pharmaceuticals
15.3.1 Product Description
15.3.2 Other Developmental Activities
15.3.3 Clinical Development
15.3.4 Clinical Trials Information
15.3.5 Safety and Efficacy
15.3.6 Product Profile
15.4 MultiStem: Athersys
15.4.1 Product Description
15.4.2 Other Developmental Activities
15.4.3 Clinical Development
15.4.4 Clinical Trials Information
15.4.5 Safety and Efficacy
15.4.6 Product Profile
15.5 Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
15.5.1 Product Description
15.5.2 Other Developmental Activities
15.5.3 Clinical Development
15.5.4 Clinical Trials Information
15.5.5 Safety and Efficacy
15.5.6 Product Profile
15.6 Ultomiris (ravulizumab-cwvz): Alexion Pharma
15.6.1 Product Description
15.6.2 Other Developmental Activities
15.6.3 Clinical Development
15.6.4 Product Profile
15.7 Soliris (eculizumab): Alexion Pharma
15.7.1 Product Description
15.7.2 Other Developmental Activities
15.7.3 Clinical Development
15.7.4 Product Profile

16 Unknown Status
16.1 Ulinastatin: Techpool Bio-Pharma
16.1.1 Product Description
16.1.2 Other Developmental Activities
16.1.3 Clinical Development
16.1.4 Clinical Trials Information
16.1.5 Product Profile

17 COVID-19 associated with ARDS: Emerging Drugs
17.1 L-citrulline: Asklepion Pharmaceuticals
17.1.1 Product Description
17.1.2 Other Developmental Activities
17.1.3 Clinical Development
17.1.4 Product Profile
17.2 Cholecalciferol: Mylan Laboratories
17.2.1 Product Description
17.2.2 Clinical Development
17.2.3 Product Profile
17.3 Ruxolitinib: Incyte Corporation/Novartis
17.3.1 Product Description
17.3.2 Other Developmental Activities
17.3.3 Clinical Development
17.3.4 Safety and Efficacy
17.3.5 Product Profile
17.4 BDB-001: Staidson (Beijing) Biopharmaceuticals
17.4.1 Product Description
17.4.2 Other Developmental Activities
17.4.3 Clinical Development
17.4.4 Product Profile
17.5 RLF-100 (aviptadil): NeuroRx/Relief Therapeutics
17.5.1 Product Description
17.5.2 Other Developmental Activities
17.5.3 Clinical Development
17.5.4 Safety and Efficacy
17.5.5 Product Profile
17.6 Zavegepant/Vazegepant: Biohaven Pharmaceutical
17.6.1 Product Description
17.6.2 Other Developmental Activities
17.6.3 Clinical Development
17.6.4 Product Profile
17.7 Metablok (LSALT peptide): Arch Biopartners
17.7.1 Product Description
17.7.2 Other Developmental Activities
17.7.3 Clinical Development
17.7.4 Safety and Efficacy
17.7.5 Product Profile
17.8 Lenzilumab: Humanigen
17.8.1 Product Description
17.8.2 Other Developmental Activities
17.8.3 Clinical Development
17.8.4 Safety and Efficacy
17.8.5 Product Profile
17.9 Actemra/RoActemra (Tocilizumab): Roche Pharma AG
17.9.1 Product Description
17.9.2 Other Developmental Activities
17.9.3 Clinical Development
17.9.4 Safety and Efficacy
17.9.5 Product Profile
17.10 DSTAT (Dociparastat sodium): Chimerix
17.10.1 Product Description
17.10.2 Other Developmental Activities
17.10.3 Clinical Development
17.10.4 Product Profile
17.11 Pemziviptadil (PB1046): PhaseBio Pharmaceuticals
17.11.1 Product Description
17.11.2 Other Developmental Activities
17.11.3 Clinical Development
17.11.4 Safety and Efficacy
17.11.5 Product Profile
17.12 ExoFlo (DB-001): Direct Biologics
17.12.1 Product Description
17.12.2 Other Developmental Activities
17.12.3 Clinical Development
17.12.4 Safety and Efficacy
17.12.5 Product Profile
17.13 Veru-111: Veru
17.13.1 Product Description
17.13.2 Clinical Development
17.13.3 Safety and Efficacy
17.13.4 Product Profile
17.14 Tradipitant: Vanda Pharmaceuticals
17.14.1 Product Description
17.14.2 Other Developmental Activities
17.14.3 Clinical Development
17.14.4 Safety and Efficacy
17.14.5 Product Profile
17.15 Brexanolone: Sage Therapeutics
17.15.1 Product Description
17.15.2 Other Developmental Activities
17.15.3 Clinical Development
17.15.4 Product Profile
17.16 Mavrilimumab: Kiniksa Pharmaceuticals
17.16.1 Product Description
17.16.2 Other Developmental Activities
17.16.3 Clinical Development
17.16.4 Safety and Efficacy
17.16.5 Product Profile
17.17 Human immunoglobulin: Laboratoire français de Fractionnement et de Biotechnologies (LFB)
17.17.1 Product Description
17.17.2 Clinical Development
17.17.3 Product Profile
17.18 Remestemcel-L: Mesoblast Limited
17.18.1 Product Description
17.18.2 Other Developmental Activities
17.18.3 Clinical Development
17.18.4 Product Profile
17.19 PLX-PAD: Pluristem Therapeutics
17.19.1 Product Description
17.19.2 Other Developmental Activities
17.19.3 Clinical Development
17.19.4 Safety and Efficacy
17.19.5 Product Profile
17.20 CERC-002: Cerecor
17.20.1 Product Description
17.20.2 Other Developmental Activities
17.20.3 Clinical Development
17.20.4 Safety and Efficacy
17.20.5 Product Profile
17.21 TD-0903: Theravance Biopharma
17.21.1 Product Description
17.21.2 Clinical Development
17.21.3 Product Profile
17.22 ILT101: ILTOO Pharma
17.22.1 Product Description
17.22.2 Clinical Development
17.22.3 Product Profile

18 Discontinued Products
18.1 APN01 (GSK2586881): Apeiron Biologics/GlaxoSmithKline
18.1.1 Product Description
18.1.2 Other Developmental Activities
18.1.3 Clinical Development
18.1.4 Safety and Efficacy
18.1.5 Product Profile
18.2 GSK2862277: GlaxoSmithKline
18.2.1 Product Description
18.2.2 Other Developmental Activities
18.2.3 Clinical Development
18.2.4 Safety and Efficacy
18.2.5 Product Profile
18.3 Remodulin (Treprostinil Inhalation Solution): United Therapeutics
18.3.1 Product Description
18.3.2 Other Developmental Activities
18.3.3 Clinical Development
18.3.4 Clinical Trials Information
18.3.5 Product Profile

19 Acute Respiratory Distress Syndrome (ARDS): 7MM Market Analysis
19.1 Key Findings
19.2 Current Market Size: Forecast Assumptions
19.3 Market Size of ARDS in the 7MM countries
19.4 Market Size of ARDS by therapies in the 7MM

20 Attribute Analysis

21 Key Emerging Therapies: Market Forecast Assumptions

22 United States: Market Outlook
22.1 United States Market Size
22.1.1 Total Market size of ARDS
22.1.2 Market Size of ARDS by Therapies in the US

23 EU-5 Countries: Market Outlook
23.1 Germany Market Size
23.1.1 Total Market Size of ARDS
23.1.2 Market Size of ARDS by Therapies in Germany
23.2 France Market Size
23.2.1 Total Market Size of ARDS
23.2.2 Market Size of ARDS by Therapies in France
23.3 Italy Market Size
23.3.1 Total Market Size of ARDS
23.3.2 Market Size of ARDS by Therapies in Italy
23.4 Spain Market Size
23.4.1 Total Market Size of ARDS
23.4.2 Market Size of ARDS by Therapies in Spain
23.5 United Kingdom Market Size
23.5.1 Total Market Size of ARDS
23.5.2 Market Size of ARDS by Therapies in the UK

24 Japan Market Outlook
24.1 Japan Market Size
24.1.1 Total Market Size of ARDS
24.1.2 Market Size of ARDS by Therapies in Japan

25 Access and Reimbursement

26 Market Drivers

27 Market Barriers

28 SWOT Analysis

29 Appendix
29.1 Report Methodology

30 Publisher Capabilities

31 Disclaimer

32 About the PublisherList of Tables
Table 1 Summary of Acute Respiratory Distress Syndrome (ARDS) Market, Epidemiology and Key Events (2017-2030)
Table 2 Definition of Acute Respiratory Distress Syndrome (ARDS)
Table 3 American European Consensus Conference Criteria for Acute Lung Injury (ALI) and the Acute Respiratory Distress Syndrome (ARDS)
Table 4 Berlin Definition of Mild, Moderate, and Severe Acute Respiratory Distress Syndrome (ARDS)
Table 5 Factors That Distinguish ARDS, CHF, and Pneumonia
Table 6 Total Incident Population of ARDS in the 7MM (2017-2030)
Table 7 Severity-specific Incident Population of ARDS in the 7MM (2017-2030)
Table 8 Total Incident Population of ARDS in the US (2017-2030)
Table 9 Severity-specific Incident Population of ARDS in the US (2017-2030)
Table 10 Incidence of ARDS by Risk Factors in the US (2017-2030)
Table 11 Total Incident Population of ARDS in Germany (2017-2030)
Table 12 Severity-specific Incident Population of ARDS in Germany (2017-2030)
Table 13 Incidence of ARDS by Risk Factors in Germany (2017-2030)
Table 14 Total Incident Population of ARDS in France (2017-2030)
Table 15 Severity-specific Incident Population of ARDS in France (2017-2030)
Table 16 Incidence of ARDS by Risk Factors in France (2017-2030)
Table 17 Total Incident Population of ARDS in Italy (2017-2030)
Table 18 Severity-specific Incident Population of ARDS in Italy (2017-2030)
Table 19 Incidence of ARDS by Risk Factors in Italy (2017-2030)
Table 20 Total Incident Population of ARDS in Spain (2017-2030)
Table 21 Severity-specific Incident Population of ARDS in Spain (2017-2030)
Table 22 Incidence of ARDS by Risk Factors in Spain (2017-2030)
Table 23 Total Incident Population of ARDS in the UK (2017-2030)
Table 24 Severity-specific Incident Population of ARDS in the UK (2017-2030)
Table 25 Incidence of ARDS by Risk Factors in the UK (2017-2030)
Table 26 Total Incident Population of ARDS in Japan (2017-2030)
Table 27 Severity-specific Incident Population of ARDS in Japan(2017-2030)
Table 28 Incidence of ARDS by Risk Factors in Japan (2017-2030)
Table 29 Management of Acute Respiratory Distress Syndrome (ARDS)
Table 30 Spontaneous Breathing Trial: Eligibility and Weaning Parameters
Table 31 Therapeutic options for severe acute respiratory distress syndrome related to coronavirus disease 2019
Table 32 Recommendations for Specific Treatment Questions for the Management of ARDS
Table 33 The Clinical Practice Guideline for The Management of ARDS in Japan
Table 34 Recommendations by the Infectious Diseases Society of America
Table 35 Randomized trials of Methylprednisolone for ARDS prevention
Table 36 Comparison of Emerging Drugs
Table 37 Key Cross
Table 38 Traumakine, Clinical Trial Description, 2020
Table 39 Bio-11006, Clinical Trial Description, 2020
Table 40 MultiStem, Clinical Trial Description, 2020
Table 41 Solnatide (AP301), Clinical Trial Description, 2020
Table 42 Soliris, Clinical Trial Description, 2020
Table 43 Ulinastatin, Clinical Trial Description, 2020
Table 44 L-citrulline, Clinical Trial Description, 2020
Table 45 Cholecalciferol, Clinical Trial Description, 2020
Table 46 Ruxolitinib, Clinical Trial Description, 2020
Table 47 BDB-001, Clinical Trial Description, 2020
Table 48 RLF-100 (aviptadil), Clinical Trial Description, 2020
Table 49 Vazegepant, Clinical Trial Description, 2020
Table 50 LSALT peptide, Clinical Trial Description, 2020
Table 51 Lenzilumab, Clinical Trial Description, 2020
Table 52 Tocilizumab, Clinical Trial Description, 2020
Table 53 DSTAT, Clinical Trial Description, 2020
Table 54 Pemziviptadil, Clinical Trial Description, 2020
Table 55 ExoFlo (DB-001), Clinical Trial Description, 2020
Table 56 VERU-111, Clinical Trial Description, 2020
Table 57 Tradipitant, Clinical Trial Description, 2020
Table 58 Brexanolone, Clinical Trial Description, 2020
Table 59 Mavrilimumab, Clinical Trial Description, 2020
Table 60 Human Immunoglobulin, Clinical Trial Description, 2020
Table 61 Remestemcel-L, Clinical Trial Description, 2020
Table 62 PLX-PAD Clinical Trial Description, 2020
Table 63 CERC-002, Clinical Trial Description, 2020
Table 64 TD-0903, Clinical Trial Description, 2020
Table 65 ILT-101, Clinical Trial Description, 2020
Table 66 APN01 (GSK2586881), Clinical Trial Description, 2020
Table 67 GSK2862277, Clinical Trial Description, 2020
Table 68 Remodulin (Treprostinil Inhalation Solution), Clinical Trial Description, 2020
Table 69 7 Major Market Size of ARDS in the 7MM, USD Million (2017-2030)
Table 70 Market size of ARDS by therapies in the 7MM, in USD Million (2017-2030)
Table 71 Key Market Forecast Assumptions for Solnatide
Table 72 Key Market Forecast Assumptions for Multistem
Table 73 Key Market Forecast Assumptions for BIO-11006
Table 74 Key Market Forecast Assumptions for Traumakine
Table 75 Key Market Forecast Assumptions for Lenzilumab
Table 76 Key Market Forecast Assumptions for Actemra/RoActemra (Tocilizumab)
Table 77 Key Market Forecast Assumptions for RLF-100 (aviptadil)
Table 78 Key Market Forecast Assumptions for Ruxolitinib
Table 79 Key Market Forecast Assumptions for Tradipitant
Table 80 Key Market Forecast Assumptions for Remestemcel-L
Table 81 United States Market Size of ARDS, USD Million (2017-2030)
Table 82 Market size of ARDS by therapies in the US, in USD Million (2017-2030)
Table 83 Germany Market Size of ARDS, in USD Million (2017-2030)
Table 84 Market size of ARDS by therapies in Germany, in USD Million (2017-2030)
Table 85 France Market Size of ARDS, in USD Million (2017-2030)
Table 86 Market size of ARDS by therapies in France, in USD Million (2017-2030)
Table 87 Italy Market Size of ARDS, in USD Million (2017-2030)
Table 88 Market size of ARDS by therapies in Italy, in USD Million (2017-2030)
Table 89 Spain Market Size of ARDS, in USD Million (2017-2030)
Table 90 Market size of ARDS by therapies in Spain, in USD Million (2017-2030)
Table 91 United Kingdom Market Size of ARDS, in USD Million (2017-2030)
Table 92 Market size of ARDS by therapies in the UK, in USD Million (2017-2030)
Table 93 Japan Market Size of ARDS, in USD Million (2017-2030)
Table 94 Market size of ARDS by therapies in Japan, in USD Million (2017-2030)List of Figures
Figure 1 Risk factors of Acute Respiratory Distress Syndrome (ARDS)
Figure 2 A simplified model of the pathogenesis of ARDS
Figure 3 Effects of Mast Cell Activation
Figure 4 Total Incident Population of ARDS in the 7MM (2017-2030)
Figure 5 Severity specific Incident Population of ARDS in the 7MM (2017-2030)
Figure 6 Total Incident Population of ARDS in the US (2017-2030)
Figure 7 Severity-specific Incidence of ARDS in the US (2017-2030)
Figure 8 Incidence of ARDS by Risk Factors in the US (2017-2030)
Figure 9 Total Incident Population of ARDS in Germany (2017-2030)
Figure 10 Severity-specific Incidence of ARDS in Germany (2017-2030)
Figure 11 Incident Population of ARDS by Risk Factors in Germany (2017-2030)
Figure 12 Total Incident Population of ARDS in France (2017-2030)
Figure 13 Severity-specific Incidence of ARDS in France (2017-2030)
Figure 14 Incident Population of ARDS by Risk Factors in France (2017-2030)
Figure 15 Total Incident Population of ARDS in Italy (2017-2030)
Figure 16 Severity-specific Incidence of ARDS in Italy (2017-2030)
Figure 17 Incidence of ARDS by Risk Factors in Italy (2017-2030)
Figure 18 Total Incident Population of ARDS in Spain (2017-2030)
Figure 19 Severity-specific Incidence of ARDS in Spain (2017-2030)
Figure 20 Incident Population of ARDS by Risk Factors in Spain (2017-2030)
Figure 21 Total Incident Population of ARDS in the UK (2017-2030)
Figure 22 Severity-specific Incidence of ARDS in the UK (2017-2030)
Figure 23 Incident Population of ARDS by Risk Factors in the UK (2017-2030)
Figure 24 Total Incident Population of ARDS in Japan (2017-2030)
Figure 25 Severity-specific Incidence of ARDS in Japan (2017-2030)
Figure 26 Incident Population of ARDS by Risk Factors in Japan (2017-2030)
Figure 27 Treatment Algorithm for ARDS
Figure 28 Unmet Needs of ARDS
Figure 29 Market Size of ARDS in the 7MM in USD Million (2017-2030)
Figure 30 Market Size of ARDS by therapies in the 7MM in USD Million (2017-2030)
Figure 31 Market Size of ARDS in the US, USD Millions (2017-2030)
Figure 32 Market Size of ARDS by therapies in the United States in USD Million (2017-2030)
Figure 33 Market Size of ARDS in Germany, USD Millions (2017-2030)
Figure 34 Market Size of ARDS by therapies in Germany in USD Million (2017-2030)
Figure 35 Market Size of ARDS in France, USD Millions (2017-2030)
Figure 36 Market Size of ARDS by therapies in France in USD Million (2017-2030)
Figure 37 Market Size of ARDS in Italy, USD Millions (2017-2030)
Figure 38 Market Size of ARDS by therapies in Italy in USD Million (2017-2030)
Figure 39 Market Size of ARDS in Spain, USD Millions (2017-2030)
Figure 40 Market Size of ARDS by therapies in Spain in USD Million (2017-2030)
Figure 41 Market Size of ARDS in the UK, USD Millions (2017-2030)
Figure 42 Market Size of ARDS by therapies in the UK in USD Million (2017-2030)
Figure 43 Market Size of ARDS in Japan, USD Millions (2017-2030)
Figure 44 Market Size of ARDS by therapies in Japan in USD Million (2017-2030)
Figure 45 Market Drivers
Figure 46 Market Barriers
Figure 47 Acute respiratory distress syndrome (ARDS) SWOT Analysis

Executive Summary

Country Wise-Acute Respiratory Distress Syndrome (ARDS) Epidemiology

The epidemiology segment also provides the Acute Respiratory Distress Syndrome (ARDS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Acute Respiratory Distress Syndrome (ARDS) Drug Chapters

The drug chapter segment of the Acute Respiratory Distress Syndrome (ARDS) report encloses the detailed analysis of Acute Respiratory Distress Syndrome (ARDS) marketed drugs and mid- and late-stage pipeline drugs. It also helps to understand the Acute Respiratory Distress Syndrome (ARDS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Acute Respiratory Distress Syndrome (ARDS) Emerging Drugs

Traumakine: Faron Pharmaceuticals
Interferon-beta-1a - also known as Traumakine; FP-1201-lyo; MR11A8; FP-1201; Recombinant Human IFN Beta-1a - is under development by Faron Pharmaceuticals as its lead drug candidate. It is a lyophilized powder form of recombinant human IFN beta-1a reconstituted in water for injection. It is administered intravenously, and targets the Interferon-beta receptor 1, activating its action. In January 2018, Faron Pharmaceuticals received Fast Track designation from the US Food and Drug Administration (FDA) for Traumakine, for the treatment of ARDS. The drug is in phase III (CALIBER Global Study) clinical developmental trial for the patients with ARDS.

BIO-11006: BioMarck Pharmaceuticals
BioMarck Pharmaceuticals is developing its lead compound BIO-11006 under the Phase II stage of development for the treatment of Adult Respiratory Distress Syndrome (ARDS). Biomarck's BIO-11006 is a novel, highly soluble, patented, 10 amino acid peptides. It acts as a MARCKS (Myristoylated alanine-rich C kinase substrate) protein inhibitor and is being developed to specifically target the MARCKS protein to inhibit cancer cell division and movement. Furthermore, it is a water-soluble, stable aerosolized anti-MARCKS peptide inhalation solution that involves aerosolized delivery of either the active drug or placebo by the “Aeroneb Pro nebulizer.”

MultiStem: Athersys
MultiStem - also known as AMI MultiStem; HLCM 051 and PF-05285401 - is a patented regenerative product which can promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage and restore immune system balance. MultiStem is under development by Athersys and is currently in the Phase II stage for the treatment of Acute Respiratory Distress Syndrome. Currently, the US FDA granted Fast Track designation to Athersys for its clinical program evaluating MultiStem cell therapy for the treatment of ARDS.

Solnatide: Apeptico Forschung und Entwicklung GmbH
Solnatide (AP301; synonym to TNF-derived TIP-peptide) under development by Apeptico Forschung und Entwicklung GmbH is a synthetic molecule whose structure bases on the lectin-like domain of the Human Tumor Necrosis Factor α. The AP301 peptide is water-soluble and can be administered into the lung by oral inhalation. The drug is conducting phase II clinical developmental trial in patients with ARDS.

Apart from these, Lenzilumab, tocilizumab (TCZ), aviptadil, ruxolitinib, tradipitant, and remestemcel-L, are the other pipeline therapies, which are expected to enter the market in the forecasted period that will be targeting the COVID-19 associated ARDS cases.

Lenzilumab: Humanigen, Inc.

Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate that is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health for its COVID-19 Big Effect Trial.

Actemra/RoActemra (Tocilizumab): Roche Pharma AG
Actemra/RoActemra (Tocilizumab) is another investigational molecule that is in phase III stage of development for SARS-CoV-2 infection and evidence of systemic inflammation. From some studies, it has been observed that Tocilizumab can be a suitable and effective therapy for severe cases of COVID-19 associated with acute respiratory distress syndrome.

Acute Respiratory Distress Syndrome (ARDS) Market Outlook

Despite recent advances in critical care, the mortality due to ARDS varies from 35% to 45% in various studies. The mortality has been reported to be associated with organ failure, sepsis, age, and associated comorbid illness. The treatment of ARDS involves general supportive measures, ventilator strategies, and appropriate treatment of the underlying condition. Besides general supportive measures, pharmacological interventions are commonly considered throughout ARDS. Although research involving the investigation of drug candidates is being carried out for over a decade, only a few pharmacological therapies have emerged for ARDS. In the off-label treatment options, STATIN therapy, NMBAs, and glucocorticosteroids are recommended because there is no approved therapy for this indication yet.

The Acute Respiratory Distress Syndrome (ARDS) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Acute Respiratory Distress Syndrome (ARDS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Acute Respiratory Distress Syndrome (ARDS) market trend of each late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Acute Respiratory Distress Syndrome (ARDS) 7MM market is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Acute Respiratory Distress Syndrome (ARDS) 7MM market.

• According to the publisher estimates, the United States accounts for the largest market size of Acute Respiratory Distress Syndrome (ARDS), in comparison to Japan and EU5 (Germany, Italy, France, UK and Spain).
• The market size of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets was 917.81 Million in 2017.
• Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of ARDS and awareness of the disease.

The United States Market Outlook

This section provides the total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in Japan are provided.

Acute Respiratory Distress Syndrome (ARDS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome (ARDS) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Respiratory Distress Syndrome (ARDS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Respiratory Distress Syndrome (ARDS) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Acute Respiratory Distress Syndrome (ARDS) emerging therapies.

Competitive Intelligence Analysis

The publisher performs competitive and market intelligence analysis of the Acute Respiratory Distress Syndrome (ARDS) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the Acute Respiratory Distress Syndrome (ARDS) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute Respiratory Distress Syndrome (ARDS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Acute Respiratory Distress Syndrome (ARDS) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acute Respiratory Distress Syndrome (ARDS) market.

Report Highlights

• Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is anticipated to rise in the forecasted period (2017-2030).
• The market for ARDS in the 7MM is projected to rise during the study period (2017-2030).
• Dynamic research and developmental activity with 60+ companies in the pipeline at different stages.
• In the coming years, Acute Respiratory Distress Syndrome (ARDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Acute Respiratory Distress Syndrome (ARDS). Launch of emerging therapies will significantly impact the Acute Respiratory Distress Syndrome (ARDS) market.
• The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Acute Respiratory Distress Syndrome (ARDS) Report Insights

• Patient Population
• Therapeutic Approaches
• Acute Respiratory Distress Syndrome (ARDS) Pipeline Analysis
• Acute Respiratory Distress Syndrome (ARDS) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Acute Respiratory Distress Syndrome (ARDS) Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Acute Respiratory Distress Syndrome (ARDS) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Acute Respiratory Distress Syndrome (ARDS) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Acute Respiratory Distress Syndrome (ARDS) market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Acute Respiratory Distress Syndrome (ARDS) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Acute Respiratory Distress Syndrome (ARDS) market size during the forecast period (2020-2030)?
• At what CAGR, the Acute Respiratory Distress Syndrome (ARDS) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
• What would be the Acute Respiratory Distress Syndrome (ARDS) market outlook across the 7MM during the forecast period (2020-2030)?
• What would be the Acute Respiratory Distress Syndrome (ARDS) market growth till 2030, and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of Acute Respiratory Distress Syndrome (ARDS)?
• What is the historical Acute Respiratory Distress Syndrome (ARDS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Acute Respiratory Distress Syndrome (ARDS) at the 7MM level?
• What will be the growth opportunities across the 7MM for the patient population pertaining to ARDS?
• Out of the countries mentioned above, which country would have the highest prevalent population of Acute Respiratory Distress Syndrome (ARDS) during the forecast period (2020-2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the treatment of Acute Respiratory Distress Syndrome (ARDS) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Acute Respiratory Distress Syndrome (ARDS) in the US and Europe?
• What are the Acute Respiratory Distress Syndrome (ARDS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
• How many therapies are developed by each company for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
• How many emerging therapies are in the mid-stage and late-stage of development for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Respiratory Distress Syndrome (ARDS) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Respiratory Distress Syndrome (ARDS) and their status?
• What are the key designations that have been granted for the emerging therapies for Acute Respiratory Distress Syndrome (ARDS)?
• What are the 7MM historical and forecasted market of Acute Respiratory Distress Syndrome (ARDS)?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome (ARDS).
• To understand the future market competition in the ARDS market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) market.
• To understand the future market competition in the Acute Respiratory Distress Syndrome (ARDS) market.

List of Companies

• Faron Pharmaceuticals
• PhaseBio Pharmaceuticals
• Sage Therapeutics
• Chimerix
• Direct Biologics
• Kiniksa Pharmaceuticals
• Pluristem Therapeutics
• Alexion Pharmaceuticals
• Biomarck Pharmaceuticals
• Athersys
• Veru
• Apeptico Forschung und Entwicklung GmbH
• Alexion Pharmaceuticals
• Humanigen, Inc.
• Roche Pharma AG
• Alexion
• Mylan Laboratories
• Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
• Laboratoire français de Fractionnement et de Biotechnologies
• Ache Laboratorios Farmaceuticos
• Implicit Bioscience
• Alexion
• NeuroRx/Relief Therapeutics
• CytoDyn
• Kiniksa
• Biohaven Pharmaceutical Holding Co. Ltd.
• Kinevant Sciences GmbH/Roivant Sciences
• Iltoo Pharma
• Eli Lilly and Company
• Merck/Eli Lilly
• Apeiron Biologics
• Roche AG
• aTyr Pharma
• Algernon Pharmaceuticals
• Histocell, S.L.
• Cellenkos Inc
• Celularity Inc.; Sorrento Therapeutics Inc.; Lung Biotechnology PBC, a subsidiary of United Therapeutics Corp.
• Hospital to Academy of Military Medical Sciences/Ivy Institute of Stem Cells Co. Ltd
• Lattice Biologics Ltd.
• Meridigen Biotech
• Theravance Biopharma,
• Mesoblast Limited
• Aqualung Therapeutics Corp.
• Diffusion Pharmaceuticals Inc.; University of Virginia
• Lamellar Biomedical Ltd.
• Leading Biosciences Inc.
• Mannkind Corp.; Immix Biopharma Inc.
• Medicinova Inc.
• Bioxytran Inc.
• Mallinckrodt plc
• GEn1E Lifesciences
• ZyVersa Therapeutics
• Quark Pharmaceuticals
• Navigen pharmaceuticals
• XORTX Therapeutics
• Tiziana
• Bioaegis Therapeutics Inc.
• Caladrius Biosciences Inc.
• Cyclacel Pharmaceuticals
• Mallinckrodt /Novoteris LLC
• Noveome Biotherapeutics
• Windtree Therapeutics
• Ampio Pharmaceuticals Inc.
• Cerecor Inc.
• Predictive Biotech, of Salt Lake City, a subsidiary of Predictive Technology Group
• Pharmazz
• Noxopharm Co.
• GlaxoSmithKline

• Ache Laboratorios Farmaceuticos
• Alexion
• Algernon Pharmaceuticals
• Ampio Pharmaceuticals Inc.
• Apeiron Biologics
• Apeptico Forschung und Entwicklung GmbH
• Aqualung Therapeutics Corp.
• Athersys
• aTyr Pharma
• Bioaegis Therapeutics Inc.
• Biohaven Pharmaceutical Holding Co. Ltd.
• Biomarck Pharmaceuticals
• Bioxytran Inc.
• Caladrius Biosciences Inc.
• Cellenkos Inc
• Celularity Inc.; Sorrento Therapeutics Inc.; Lung Biotechnology PBC, a subsidiary of United Therapeutics Corp.
• Cerecor Inc.
• Chimerix
• Cyclacel Pharmaceuticals
• CytoDyn
• Diffusion Pharmaceuticals Inc.; University of Virginia
• Direct Biologics
• Eli Lilly and Company
• Faron Pharmaceuticals
• GEn1E Lifesciences
• GlaxoSmithKline
• Histocell, S.L.
• Hospital to Academy of Military Medical Sciences/Ivy Institute of Stem Cells Co. Ltd
• Humanigen, Inc.
• Iltoo Pharma
• Implicit Bioscience
• Kinevant Sciences GmbH/Roivant Sciences
• Kiniksa Pharmaceuticals
• Laboratoire français de Fractionnement et de Biotechnologies
• Lamellar Biomedical Ltd.
• Lattice Biologics Ltd.
• Leading Biosciences Inc.
• Mallinckrodt /Novoteris LLC
• Mannkind Corp.; Immix Biopharma Inc.
• Medicinova Inc.
• Merck/Eli Lilly
• Meridigen Biotech
• Mesoblast Limited
• Mylan Laboratories
• Navigen pharmaceuticals
• NeuroRx/Relief Therapeutics
• Noveome Biotherapeutics
• Noxopharm Co.
• Pharmazz
• PhaseBio Pharmaceuticals
• Pluristem Therapeutics
• Predictive Biotech, of Salt Lake City, a subsidiary of Predictive Technology Group
• Quark Pharmaceuticals
• Roche AG
• Roche Pharma AG
• Sage Therapeutics
• Theravance Biopharma,
• Tiziana
• Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
• Veru
• Windtree Therapeutics
• XORTX Therapeutics
• ZyVersa Therapeutics